Immuron Plans Phase 3 trial for IMM-124E to Prevent Travelers’ Diarrhea
Immuron Limited - American Depositary Shares (IMRN)
US:NASDAQ Investor Relations:
immuron.com/investor-centre/business-overview
Company Research
Source: GlobeNewswire
Key Points Immuron completes first meeting with FDA on development of IMM-124E as product to specifically prevent Travelers’ Diarrhea (TD)Phase 3 clinical trial of IMM-124E to prevent TD planned for 2020Previous clinical trial data on IMM-124E from earlier studies provides support for development as treatment to prevent TD MELBOURNE, Australia, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunoglobulin therapeutics for the treatment of gut mediated diseases, today announced that the company recently completed a Pre-IND meeting with the U.S. Food and Drug administration (FDA) regarding its investigational drug IMM-124E which the company is developing to treat travelers’ diarrhea (TD). Following the FDA’s guidance and feedback, the Company now plans to file an investigational new drug (IND) application for IMM-124E to prevent TD during the first half of 2020, foll
Show less
Read more
Impact Snapshot
Event Time:
IMRN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMRN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMRN alerts
High impacting Immuron Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
IMRN
News
- Immuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Summit Microcap EventGlobeNewswire
- Immuron Limited to Present at November 21st Virtual Investor Summit Microcap EventAccesswire
- Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare ConferenceGlobeNewswire
- Immuron Travelan® continued strong sales growthGlobeNewswire
- NMRC Reports Results for Campylobacter Controlled Human Infection Model StudyGlobeNewswire
IMRN
Sec Filings
- 11/22/24 - Form 6-K
- 11/18/24 - Form 6-K
- 11/14/24 - Form 6-K
- IMRN's page on the SEC website